Vol. 5 No. 10 (2025)
Reimbursement Reviews

Pembrolizumab (Keytruda)

decorative image of the issue cover

Published October 24, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses pembrolizumab (Keytruda), 100 mg/4 mL vial, solution for infusion.
  • Indication: For the treatment of adult patients with resectable stage II, IIIA, or IIIB (T3 to 4N2) non–small cell lung cancer in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery.